However, a recent phase I/II study of 30 AML patients (3 in PR, 27 in CR with high-risk of relapse) administered a dendritic cell WT1 vaccine in the adjuvant setting and found that 8 of 23 patients with elevated WT1 transcript had a molecular response following vaccination, with five of these eight patients subsequently maintaining remission at a median follow-up of 63 months [76]. Here, WT1 is linked to acute myeloid leukemia.